Report of Foreign Issuer (6-k)
September 17 2019 - 10:20AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of September 2019
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: September 17, 2019 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure Announces Launch of New and Improved
ReDS™ PRO
WINNIPEG, Sept. 17, 2019 /CNW/ - Medicure Inc.
("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to
announce the launch of the ReDSTM PRO ("ReDSTM PRO") system, the next generation of lung
fluid management technology for heart failure. The debut of the new system took place at the recent Heart Failure Society of America
("HFSA") conference in Philadelphia, PA. ReDSTM PRO is optimized for the point-of-care market,
designed for use in hospitals and sub-acute facilities. ReDSTM PRO utilizes non-invasive low energy radio frequency
technology that produces reliable fluid volume readings after only 45 seconds of measurement. The ReDSTM PRO can
be utilized across the continuum of hospital care, from the emergency department to discharge and subacute rehabilitation.
Medicure previously announced, on January 28,
2019, that it had entered an agreement with Sensible Medical Innovations Inc. ("Sensible") to become the exclusive marketing
partner for the ReDS™ point of care system in the United States, a non-invasive, FDA-cleared medical device that provides
an accurate, actionable and absolute measurement of lung fluid which is important in the management of congestive heart failure.
The ReDSTM PRO represents the next generation of this device.
"Medicure was excited to introduce the
ReDSTM PRO at the HFSA conference in an effort to improve the quality of life of heart failure patients. The device
is being sold by Medicure directly to hospitals through our existing commercial operation and supports our mission of being a significant,
value-based, cardiovascular company focused on the U.S. market." commented Dr. Albert Friesen, Chief Executive Officer
for Medicure.
Medicure continues to hold a 7.71% equity stake,
on a fully diluted basis, in Sensible.
About ReDSTM PRO System
The ReDSTM PRO is an accurate
measurement tool to evaluate pulmonary congestion providing additional information to assist a physician in their assessment of
a patient's condition. Assessment with the aid of ReDSTM technology has helped physicians at facilities across
the country to better manage their patients' heart failure, with the goal of avoiding readmissions. For more information please
visit www.medicure.com/reds.
About Medicure
Medicure is a pharmaceutical company focused
on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the
marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin)
tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma
Inc. For more information on Medicure please visit www.medicure.com.
About Sensible
Sensible is a market leader in medical radar
monitoring and imaging technology. ReDS™ was adapted for medical use from military 'see-through-wall' technology. The technology
is well-positioned to be a difference maker in a wide range of applications and to become the next-generation lung fluid monitoring
modality.
www.sensible-medical.com
To be added to Medicure's e-mail list, please
visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.
View original content:http://www.prnewswire.com/news-releases/medicure-announces-launch-of-new-and-improved-reds-pro-300919842.html
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/September2019/17/c6957.html
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 09:59e 17-SEP-19
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Sep 2023 to Sep 2024